Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

74737 1534256234HCLSReviewPortugalAugust2018.pdf
Energy Boardroom

ATS 2014: InterMune, Boehringer face off in IPF

19.05.2014 / Scripintelligence

InterMune's idiopathic pulmonary fibrosis (IPF) drug pirfenidone may have a survival benefit over Boehringer Ingelheim's IPF treatment nintedanib, but Phase III results presented at the American Thoracic Society (ATS) 2014 Conference in San Diego make it…

LATEST ISSUE

DOWNLOAD

Most Read

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: